Fusen Pharmaceutical Company Limited (1652.HK)

HKD 0.81

(-2.41%)

Net Income Summary of Fusen Pharmaceutical Company Limited

Fusen Pharmaceutical Company Limited's latest annual net income in 2023 was -36.27 Million CNY , down -4.68% from previous year.
Fusen Pharmaceutical Company Limited's latest quarterly net income in 2024 Q2 was -18.47 Million CNY , down 0.0% from previous quarter.
Fusen Pharmaceutical Company Limited reported an annual net income of -34.65 Million CNY in 2022, down -308.19% from previous year.
Fusen Pharmaceutical Company Limited reported an annual net income of 16.64 Million CNY in 2021, down -76.27% from previous year.
Fusen Pharmaceutical Company Limited reported a quarterly net income of -18.47 Million CNY for 2024 Q1, up 29.95% from previous quarter.
Fusen Pharmaceutical Company Limited reported a quarterly net income of 8.22 Million CNY for 2023 Q1, up 159.69% from previous quarter.

Annual Net Income Chart of Fusen Pharmaceutical Company Limited (2023 - 2015)

Historical Annual Net Income of Fusen Pharmaceutical Company Limited (2023 - 2015)

Year	Net Income	Net Income Growth
2023	-36.27 Million CNY	-4.68%
2022	-34.65 Million CNY	-308.19%
2021	16.64 Million CNY	-76.27%
2020	70.13 Million CNY	31.25%
2019	53.43 Million CNY	-47.55%
2018	101.88 Million CNY	5.23%
2017	96.82 Million CNY	1.84%
2016	95.07 Million CNY	111.84%
2015	44.87 Million CNY	0.0%

Year	Net Income	Net Income Growth
2024 Q2	-18.47 Million CNY	0.0%
2024 Q1	-18.47 Million CNY	29.95%
2023 Q1	8.22 Million CNY	159.69%
2023 Q4	-26.36 Million CNY	0.0%
2023 FY	-36.27 Million CNY	-4.68%
2023 Q2	8.22 Million CNY	0.0%
2023 Q3	-26.36 Million CNY	-420.45%
2022 Q1	-3.51 Million CNY	74.2%
2022 FY	-34.65 Million CNY	-308.19%
2022 Q3	-13.78 Million CNY	-291.76%
2022 Q2	-3.51 Million CNY	0.0%
2022 Q4	-13.78 Million CNY	0.0%
2021 Q2	21.95 Million CNY	0.0%
2021 Q3	-13.63 Million CNY	-162.1%
2021 FY	16.64 Million CNY	-76.27%
2021 Q4	-13.63 Million CNY	0.0%
2021 Q1	21.95 Million CNY	24.78%
2020 Q4	17.59 Million CNY	0.0%
2020 Q2	17.46 Million CNY	0.0%
2020 FY	70.13 Million CNY	31.25%
2020 Q1	17.46 Million CNY	17.31%
2020 Q3	17.59 Million CNY	0.75%
2019 FY	53.43 Million CNY	-47.55%
2019 Q4	14.88 Million CNY	0.0%
2019 Q3	14.88 Million CNY	25.89%
2019 Q2	11.82 Million CNY	0.0%
2019 Q1	11.82 Million CNY	-51.11%
2018 Q3	24.19 Million CNY	-9.56%
2018 Q4	24.19 Million CNY	0.0%
2018 Q1	26.74 Million CNY	10.06%
2018 Q2	26.74 Million CNY	0.0%
2018 FY	101.88 Million CNY	5.23%
2017 Q1	26.05 Million CNY	87.16%
2017 FY	96.82 Million CNY	1.84%
2017 Q4	24.3 Million CNY	0.0%
2017 Q2	26.05 Million CNY	0.0%
2016 Q1	24.04 Million CNY	0.0%
2016 Q4	13.92 Million CNY	0.0%
2016 FY	95.07 Million CNY	111.84%
2016 Q2	24.04 Million CNY	0.0%
2015 FY	44.87 Million CNY	0.0%
2015 Q3	11.5 Million CNY	0.0%
2015 Q4	24.04 Million CNY	108.97%
2015 Q2	11.5 Million CNY	0.0%
2015 Q1	11.5 Million CNY	0.0%
2014 Q4	11.5 Million CNY	0.0%

Peer Net Income Comparison of Fusen Pharmaceutical Company Limited

Name	Net Income	Net Income Difference
Pak Fah Yeow International Limited	105.03 Million HKD	134.537%
Grand Pharmaceutical Group Limited	1.87 Billion HKD	101.93%
Extrawell Pharmaceutical Holdings Limited	-162.94 Million HKD	77.737%
Wai Yuen Tong Medicine Holdings Limited	-15.35 Million HKD	-136.24%
Qianhai Health Holdings Limited	-52.7 Million HKD	31.17%
Lee's Pharmaceutical Holdings Limited	16.69 Million HKD	317.254%
Essex Bio-Technology Limited	275.25 Million HKD	113.179%
Tongfang Kontafarma Holdings Limited	-28.84 Million HKD	-25.774%
PuraPharm Corporation Limited	-106.08 Million HKD	65.803%
SSY Group Limited	1.31 Billion HKD	102.751%
JBM (Healthcare) Limited	130.46 Million HKD	127.806%
Jacobson Pharma Corporation Limited	266.96 Million HKD	113.589%
China Resources Pharmaceutical Group Limited	3.85 Billion HKD	100.941%